Thursday, October 25, 2018 8:30:00 PM
I've had it explained to me that the chemical forms are like various generations of tech with a slide showing at the base of the pyramid natural TG forms for the EPA/DHA. So, kind of like this--
4G: Emulsifications/PLs
3G: PLs, FFAs
2G: EE, rTGs
1G: natural form TGs
There's crossover between the tech generations and no consensus on the levels & which is better - all debatable. Eating a sardine would be the lowest form of tech in other words - but, its not "worse" & may also be much better than the later "tech" for the average healthy person because we would get all the peptides and other natural substances according to registered dietitians. (Like allergy "tech" - Benadryl is 1G (indiscriminate effects) while Claritin/Zyrtec/Allegra are later versions)
The board debated this topic in Feb 2018 with the posting chain
DitD: 122238
JL: 122245
Also, I can't remember the post # maybe somebody else does where the statisticians here on the board posted/commented on the wide error bars on I believe this study: 47 person emulsified cod liver oil study Dr. Calder reviewed and summarized 12 studies published between 1990-2015 and their showings on which form was "better" or "tied" on Slide 20 and went on to quickly review his unpublished small study with Dr. West on emulsified forms. Calder ppt
This has been covered in Nutra Ingredients Nutra magazine Aug 21 2018 cod liver emulsification study I like Dr. Harris' quote at the end to which form is better based on speed of uptake "So what?"
To JL's point - it first matters to marketers. GSK sponsored that cod liver oil emulsion study which makes sense. Everybody is looking for the edge with a new story to spin for growth, just like every other industry. I agree with Dan and HDG and others on here regarding AMRN which has an ideal Hollywood set-up - lipid regulator ver. 2.0 in other words, like another Star Wars movie. Investors don't have to think too hard - they figure its going to be a blockbuster (like Lovaza was).
--------------
I also agree with JL post #151371. It's about reducing systemic inflammation as UC Davis did with a horse that had laminitis and was dying which then started walking around again and was fine after treatment (but these were DHA epoxides):
Dr. Bruce Hammock horse article
Capt. Joseph R. Hibbelin, MD has done a lot of work on SI reduction in the neurosciences with Omega 3's as well (too little DHA in the brain and all the mental health issues it seems to cause). For example, people who consume high levels of fish regularly are 20% less likely to have major depression.
The arachidonic acid cascade really seems to be correlated with our poor Western diet in terms of Omega 3s for a lot of people. I've read Dr. Joseph C Maroon's book "Fish Oil: The Natural Anti-Inflammatory" and it covers much of this same material. Amazon - Dr. Maroon fish oil book He was/is still? the Pittsburgh Steeler's team neurosurgeon (U Pittsburgh).
Anyways, that's what I've been able to glean.
Recent AMRN News
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM